A Phase I/Randomized Phase II Study of Cediranib (NSC 732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Cediranib (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2017 Results of phase I part of this study (n=20) published in the Journal of Thoracic Oncology
- 10 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
- 17 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.